Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma.

Frontiers in immunology - 1 Jan 2021

Chen Lin, Zhou Qiaodan, Liu Junjie, Zhang Wei

Abstract excerpt

Background: The emergence of immune checkpoint inhibitors (ICIs) marks the beginning of a new era of immunotherapy for hepatocellular carcinoma (HCC), however, not all patients respond successfully to this treatment. A major challenge for HCC immunotherapy is the development of ways to screen for those patients that would benefit from this type of treatment and determine the optimal treatment plan for individual...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to beta Catenin
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Hepatocellular

Share to Cohort Studies

Share to Immunotherapy

Share to Liver Neoplasms

Share to Proportional Hazards Models

Source

Open in PubMed Open full text

Identifiers

PMID: 34777372
DOI: 10.3389/fimmu.2021.759565
PMCID: PMC8581472

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma.PMID 34777372Read ↗

CTNNB1-mutation-related immune gene prognostic model (CMRIPM) for hepatocellular carcinoma: Development and validationSemantic proximity Read ↗

Development and Validation of a Novel Immune-Gene Pairs Prognostic Model Associated with CTNNB1 Alteration in Hepatocellular CarcinomaSemantic proximity Read ↗

The Crosstalk Between CTNNB1 Mutation and M2 Macrophages Contribute to Hepatocellular Carcinoma Suppressive Immune MicroenvironmentSemantic proximity Read ↗

Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinomaSemantic proximity Read ↗

Multi-omics analysis reveals prognostic value of tumor mutation burden in hepatocellular carcinomaSemantic proximity Read ↗

Identification of Tumor Mutation Burden and Immune Infiltrates in Hepatocellular Carcinoma Based on Multi-Omics AnalysisSemantic proximity Read ↗

Identification of Tumor Mutation Burden and Immune Infiltrates in Hepatocellular Carcinoma Based on Multi-Omics AnalysisSemantic proximity Read ↗

Identification of Tumor Mutation Burden and Immune Infiltrates in Hepatocellular Carcinoma Based on Multi-Omics AnalysisSemantic proximity Read ↗

Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification.Semantic proximity Read ↗

Immune signature-based hepatocellular carcinoma subtypes may provide novel insights into therapy and prognosis predictionsSemantic proximity Read ↗

A Novel Immune Classification Reveals Distinct Immune Escape Mechanism and Genomic Alterations: Implications for Immunotherapy in Hepatocellular CarcinomaSemantic proximity Read ↗

CTNNB1 mutation suppresses infiltration of immune cells in hepatocellular carcinoma through miRNA-mediated regulation of chemokine expression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.